Clinical Research
person

Uffe B.

Country
Denmark
Department
Department of Respiratory Medicine

Research Overview

assignment
8
Clinical Trials ·
location_city
1
Research Sites

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
160
Sites with multiple studies

Has run more than one trial at 160 of 493 partner sites.

Specializations

Chronic Respiratory Disorders

The investigator concentrates on Chronic Obstructive Pulmonary Disease and severe eosinophilic asthma, exploring anti‑inflammatory and bronchodilator strategies to reduce exacerbations and improve lung function.

  • Inhaled corticosteroid tapering guided by eosinophil counts
  • Anti‑IL‑5 therapy (benralizumab) for eosinophilic airway inflammation
  • Novel anti‑IL‑33 antibody (astegolimab) for COPD exacerbation control
  • Triple bronchodilator combination (BGF MDI) versus dual therapy
  • Long‑acting anti‑TSLP agent (tezepelumab) in symptomatic COPD

These efforts aim to translate biomarker‑driven approaches into durable respiratory health benefits.

Oncology and Targeted Cancer Therapy

His work spans multiple solid tumours, emphasizing precision medicine for breast cancer, prostate cancer, urothelial carcinoma, and head and neck squamous cell carcinoma, with a focus on genomic‑guided agents.

  • Androgen receptor blockade (darolutamide) in high‑risk prostate disease
  • PARP inhibition (niraparib) for HRR‑mutated metastatic castration‑sensitive prostate cancer
  • Selective estrogen receptor degraders (giredestrant) combined with CDK4/6 inhibition
  • Antibody‑drug conjugate (zelenectide pevedotin) with checkpoint blockade in urothelial cancer
  • Triple‑negative breast cancer post‑neoadjuvant strategies (dato‑Dxd plus durvalumab)

The portfolio reflects a commitment to advancing molecularly targeted oncologic therapies.

Post‑operative Pain and Orthopedic Recovery

In the orthopedic arena, the investigator evaluates analgesic and anti‑inflammatory regimens to enhance recovery after hip and knee arthroplasty.

  • Short‑course non‑opioid analgesia (ibuprofen) after major joint surgery
  • Management of postoperative oral mucositis pain with topical agents (bupiZenge)
  • Assessment of temporary discontinuation of serotonergic antidepressants in surgical patients
  • Evaluation of bone‑derived mesenchymal stem cell therapy for knee osteoarthritis

These investigations target functional restoration while minimizing opioid exposure.

Cardiovascular and Metabolic Interventions

The investigator contributes to cardiovascular risk reduction studies, including post‑myocardial infarction management and metabolic modulation.

  • Beta‑blocker therapy after myocardial infarction without reduced ejection fraction (DANBLOCK)
  • Statin adjunct (atorvastatin) to adjuvant cancer therapy for disease‑free survival
  • Combination immunotherapy regimens (teclistamab + daratumumab) in multiple myeloma
  • Evaluation of cardiovascular outcomes in patients receiving novel anti‑cancer agents

These projects integrate cardiometabolic health into broader therapeutic paradigms.

Hormone‑Related and Menopausal Symptom Management

His research also addresses endocrine‑related quality‑of‑life issues, focusing on vasomotor symptoms and hormone‑driven breast cancer subtypes.

  • Non‑hormonal neurokinin‑3 antagonist (fezolinetant) for moderate to severe vasomotor symptoms
  • Targeted therapy for PIK3CA‑mutated HR+/HER2‑ advanced breast cancer
  • Evaluation of endocrine therapy‑associated hot flashes in estrogen‑receptor positive disease
  • Integration of lipid‑lowering agents (atorvastatin) with hormonal cancer regimens

These initiatives aim to alleviate treatment‑related hormonal disturbances while maintaining oncologic efficacy.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.